TACSTD2-high tumors were associated with worse OS in breast cancer (hazard ratio [HR] 1.13 [1.03-1.23], P < .007), CRC (HR 1.33 [1.24-1.42], P < .001), and pancreatic cancer (HR 1.31 [1.19-1.44]; P < .001), while this association was not observed in urothelial or hepatocellular liver cancer (P > .05; Figure 5A). Here, TACSTD2 is linked to pancreatic neoplasm.